Source: GLOBENEWSWIRE

Press Release: Rafarma Pharmaceuticals : Rafarma Pharmaceuticals (RAFA) Announces New President as Part of Pending Acquisition of Majority Interest

Read full article »
Rafarma Pharmaceuticals's Competitors | Rafarma Pharmaceuticals's News | Rafarma Pharmaceuticals's Financials

February 6, 2023

BioSpace

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy

IgGenix, Inc., a pre-clinical biotechnology company taking a revolutionary approach to directly addre... See more »

February 6, 2023

PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

Endometrial cancer is the sixth most common cancer in women worldwide and 15th most common cancer ove... See more »

February 6, 2023

BioSpace

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy

IgGenix, Inc., a pre-clinical biotechnology company taking a revolutionary approach to directly addre... See more »

February 6, 2023

PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

Endometrial cancer is the sixth most common cancer in women worldwide and 15th most common cancer ove... See more »
Stay up-to-date with the latest news on Rafarma Pharmaceuticals
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Rafarma Pharmaceuticals